Medovex Corporation to Attend BritSpine 2016 Conference

ATLANTA, GA--(Marketwired - Mar 30, 2016) - Medovex Corp. (NASDAQ: MDVX), a developer of medical technology products, today announced that as part of the Company's continuing European launch planning for the DenerveX™ System, the company will be attending BritSpine 2016, the Biennial Scientific Congress of the United Kingdom Spine Societies, being held April 6 - 8, 2016, at the Nottingham Conference Center.

The BritSpine is a highly recognized scientific congress and is attended by leading spine surgeons from the UK, including The British Association of Spine Surgeons (BASS), The British Scoliosis Society (BSS), The Society for Back Pain Research (SBPR) and other leading spine surgeons around the globe. Participants will share the latest information on best practices, innovative techniques and procedures, and new technologies in spine surgery.

Medovex will attend the meeting with its UK distributor Edge Medical, Ltd., a premier distributor in surgical spine technologies. Together, they will be demonstrating the Company's DenerveX System technology for the first time to the UK Spine Societies, supported by members of our European medical advisory board and key opinion leader Dr. Vik Kapoor of Manchester, England.

The Company's patented DenerveX System, currently in final development is designed to provide longer lasting relief of pain associated with the facet joint. Lower back pain is the second most common cause of disability in the U.S. for adults. Studies indicate that 10% of the U.S. adult population suffers from lower back pain and that 31% of lower back pain is attributed to facet joint pain.

The DenerveX System consists of the DenerveX device, a single use device, and the DenerveX Pro-40 Power Generator. The DenerveX system is designed to provide a minimally invasive treatment option which combines two actions into one device.

Mr. Manfred Sablowski, Medovex Senior Vice President Sales & Marketing, stated, "We are very excited to be participating in the BritSpine 2016 and the Associated British Spine Societies, representing one of the largest spine societies in Europe. It is clearly the place to introduce new and innovative technologies, such as our DenerveX System technology as an important part of our continued strategy and preparation for a successful EU launch."

Sablowski continued, "The BritSpine 2016 is a key meeting to connect with leading spine practitioners and to collaborate and develop relationships as we continue to proceed with our product launch in the future. The event will also importantly provide us the opportunity to continue to identify leading key opinion leaders and other early adopters, as well as continue to develop strategies that we believe will help make our future launch a success and create value for our shareholders."

DenerveX is not yet CE marked or FDA cleared and is not yet commercially available.

About Medovex

Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com

Safe Harbor Statement

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.